EMA Approves Active Biotech's Tasquinimod Trial for Myelofibrosis
Key Insights
Active Biotech (search) received EMA approval for its Phase I/II trial of tasquinimod in myelofibrosis (search) patients resistant or intolerant to JAK2 (search) inhibitors.
The open-label, multicenter study will assess tasquinimod's safety and efficacy as a monotherapy in previously treated or unsuitable patients.
Tasquinimod's disease-modifying potential is supported by preclinical data, with patient enrollment expected to begin shortly, according to Active Biotech (search).
Active Biotech (search) has secured approval from the European Medicines Agency (EMA) and institutional ethics committees to proceed with its Phase I/II clinical trial evaluating tasquinimod in patients with myelofibrosis (search) who are either refractory to or intolerant of JAK2 inhibitor therapy. This regulatory clearance paves the way for the company to initiate patient enrollment in the near future.
The open-label, multicenter study is designed to evaluate the safety and efficacy of tasquinimod when administered as a monotherapy. The patient population will consist of individuals diagnosed with myelofibrosis (search) who have previously undergone treatment with a JAK2 inhibitor or are deemed unsuitable candidates for such treatment. The primary endpoint is to assess the safety and tolerability of tasquinimod in this patient population.
Rationale for Tasquinimod in Myelofibrosis
According to CMO Erik Vahtola, the trial is underpinned by compelling preclinical evidence suggesting tasquinimod possesses disease-modifying capabilities. The study aims to address a critical unmet need in myelofibrosis (search) patients who do not respond to or cannot tolerate JAK2 (search) inhibitors, which are currently a standard treatment option.
Myelofibrosis (search) is a rare and serious bone marrow disorder that disrupts the body's normal production of blood cells. It is characterized by bone marrow scarring, leading to anemia, fatigue, and an enlarged spleen. Patients who are resistant or intolerant to JAK2 (search) inhibitors have limited treatment options, highlighting the importance of developing alternative therapies like tasquinimod.